MedTrace Logo

A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors

NCT06730659 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2024-12-12

No results posted yet for this study

Summary

Evaluate the safety and efficacy of CD70-targeting UCAR-T cells in the treatment of CD70-positive advanced solid tumors.

Conditions

  • Relapsed / Refractory Solid Tumor

Interventions

BIOLOGICAL

CHT101

CHT101: CD 70 UCAR T

Sponsors & Collaborators

  • Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.

    collaborator INDUSTRY

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-19
Primary Completion
2027-04-18
Completion
2039-04-18

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06730659 on ClinicalTrials.gov